BioAdaptives

BioAdaptives ROIC

The Return on Invested Capital (ROIC) of BioAdaptives (BDPT) as of Oct 25, 2026 is 89.25 %. In the previous year, Return on Invested Capital (ROIC) was 80.21 % — a change of 11.27% (higher).

ROIC

89.25 %

YoY

11.27%

Last updated:

Return on Invested Capital (ROIC) of BioAdaptives is 2025 89.25 % . Return on Invested Capital (ROIC) of BioAdaptives was 2024 80.21 % . It decreases by 11.27% higher compared to the previous year.

The BioAdaptives ROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROIC
Date
ROIC
Jan 1, 2018
232.15 USD
Jan 1, 2019
93.29 USD
Jan 1, 2020
120.29 USD
Jan 1, 2021
160.01 USD
Jan 1, 2022
84.57 USD
Jan 1, 2023
54.04 USD
Jan 1, 2024
80.21 USD
Jan 1, 2025
89.25 USD
The BioAdaptives ROIC history
YEARROICYoY
89.25 %+11.27%
80.21 %+48.42%
54.04 %-36.10%
84.57 %-47.15%
160.01 %+33.02%
120.29 %+28.94%
93.29 %-59.81%
232.15 %-113.02%
-1,783.14 %-1,935.30%
97.16 %-13.12%
111.83 %-101.47%
-7,599.68 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioAdaptives Stock analysis

What does BioAdaptives do? BioAdaptives, Inc. generates revenue through the sale of health and wellness products including dietary supplements, specialty food items, and devices that optimize bioelectromagnetic availability. The company markets PrimiCell and PrimiLive under a product agreement with Ferris Holding, Inc., targeting consumers seeking cognitive enhancement, fatigue reduction, and anti-aging solutions. PrimiTrim serves the weight control segment, while Equine Regen and Equine Regen Plus are in advanced testing for veterinary use. The firm also develops a dog product, expanding its wellness offerings across human and animal health markets. Ferris Holding, Inc. provides the intellectual property and products that BioAdaptives markets, including PrimiCell and PrimiLive, which are positioned for cognition, focus, and emotional wellness. The company's advanced-stage products Equine Regen and Equine Regen Plus cater to the veterinary segment, with PrimiTrim addressing weight management needs. BioAdaptives' product portfolio spans nutraceuticals, devices, and specialty foods designed to improve physical and emotional wellness across multiple consumer segments. BioAdaptives focuses on selling devices and nutraceuticals that target cognitive performance, fatigue reduction, and anti-aging, with PrimiCell and PrimiLive as key products under the Ferris agreement. The company's weight control solution PrimiTrim appeals to consumers seeking wellness through diet, while Equine Regen and Equine Regen Plus target animal health providers. The firm's development of a dog product further diversifies its offerings in the wellness market. BioAdaptives is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioAdaptives stock

Return on Invested Capital (ROIC) of BioAdaptives is 89.25 % in 2025.

Return on Invested Capital (ROIC) of BioAdaptives changed from 80.21 % to 89.25 %, representing a 11.27% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Invested Capital (ROIC) BioAdaptives since 2006 – with annual values, charts, and detailed analysis.

ROIC measures how effectively a company uses its invested capital to generate profits. A ROIC above the cost of capital creates shareholder value.

ROIC = NOPAT / Invested Capital

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Invested Capital (ROIC)'s BioAdaptives with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Invested Capital (ROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Invested Capital (ROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — BioAdaptives

All Key Metrics — BioAdaptives